Arvinas, Inc. (NASDAQ:ARVN) Insider Sells $150,724.20 in Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Ian Taylor sold 9,020 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the sale, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. This trade represents a 5.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Arvinas Trading Down 5.7 %

NASDAQ:ARVN opened at $16.75 on Tuesday. The stock has a 50 day simple moving average of $18.44 and a 200 day simple moving average of $22.85. The stock has a market cap of $1.15 billion, a P/E ratio of -6.05 and a beta of 1.88. Arvinas, Inc. has a 1-year low of $16.07 and a 1-year high of $51.51.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter in the prior year, the company earned ($2.53) earnings per share. As a group, sell-side analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Guggenheim restated a “buy” rating and set a $57.00 price objective on shares of Arvinas in a research note on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and set a $87.00 price target on shares of Arvinas in a research report on Wednesday, December 11th. BMO Capital Markets restated an “outperform” rating and issued a $82.00 price objective (down previously from $88.00) on shares of Arvinas in a research note on Wednesday, February 12th. Oppenheimer lifted their target price on Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Finally, Stephens assumed coverage on Arvinas in a report on Monday, November 18th. They set an “overweight” rating and a $55.00 target price on the stock. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $60.00.

Hedge Funds Weigh In On Arvinas

Hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. acquired a new position in shares of Arvinas during the 4th quarter worth approximately $42,332,000. Norges Bank bought a new stake in shares of Arvinas in the fourth quarter valued at approximately $23,845,000. Boxer Capital Management LLC acquired a new stake in Arvinas during the fourth quarter worth approximately $20,294,000. Braidwell LP increased its stake in Arvinas by 148.3% during the 3rd quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock worth $31,637,000 after acquiring an additional 767,242 shares during the period. Finally, RTW Investments LP increased its stake in Arvinas by 19.8% during the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company’s stock worth $63,919,000 after acquiring an additional 551,979 shares during the period. 95.19% of the stock is owned by institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.